Elongation of Very Long Chain Fatty Acids-Like 4

Alternative Names

  • ELOVL4
Back to search Result
OMIM Number

605512

NCBI Gene ID

6785

Uniprot ID

Q9GZR5

Length

32,740 bases

No. of Exons

6

Protein Name

Very long chain fatty acid elongase 4

Molecular Mass

36,829 Da

Amino Acid Count

314

Genomic Location

chr6:79,914,814-79,947,553

Gene Map Locus
6q14.1

Description

ELOVL4 gene codes for a protein that is found primarily in the retina.  This protein called ELOVL Fatty Acid Elongase 4, is a member of the ELO protein family and is produced in photoreceptors.  The ELOVL4 protein is also found in the brain and skin, but little is known about its expression in these structures.  Inside photoreceptor cells, this protein is located in a cell structure called the endoplasmic reticulum that is involved in protein production, processing, and transport.  The ELOVL4 protein plays a role in making a group of fats called very long-chain fatty acids.  The protein helps add carbon molecules to long-chain fatty acids, making them very long-chain fatty acids.

Mutations in the ELOVL4 gene create a premature stop signal in the instructions used to make the ELOVL4 protein.  As a result, the protein cannot be retained in the endoplasmic reticulum of photoreceptor cells.  Instead, the ELOVL4 protein forms clumps (aggregates).  These aggregates cannot make very long-chain fatty acids and may interfere with cell functions, ultimately leading to cell death.  Studies in animal models have shown that defective ELOVL4 proteins are unable to prevent water loss from the skin in a desiccating environment leading the animals to dehydrate very quickly and die as a result.  Mutations in this gene are implicated in different diseases, including ISQMR, a syndrome of ichthyosis, spastic quadriplegia and mental retardation, a subtype of spinocerebellar ataxia (SCA34), and a form of macular degeneration known as Stargadt Disease.

Epidemiology in the Arab World

View Map
Variant NameCountryGenomic LocationClinvar Clinical SignificanceCTGA Clinical Significance Condition(s)HGVS ExpressionsdbSNPClinvar
NM_022726.4:c.575A>GSaudi ArabiaNC_000006.12:g.79919514T>CLikely PathogenicIchthyosis, Spastic Quadriplegia, and Mental RetardationNG_009108.2:g.33085A>G; NM_022726.4:c.575A>G; NP_073563.1:p.His192Arg1774216799

Other Reports

Saudi Arabia

Aldahmesh et al. (2011) reported on an individual born to healthy first cousin consanguineous Saudi Arabian parents with recessive ELOVL4 mutation who displayed a syndrome of congenital ichthyosis, spastic quadriplegia, and mental retardation.   Biochemical analysis of fibroblast fatty aldehyde dehydrogenase (FALDH) activity was found to be normal in this patient, which suggested that this index had ‘‘pseudo-SLS’’.  Whole exome sequencing performed at 303x coverage identified a truncating nonsense mutation in exon 5 of ELOVL4, c.646C>T (p.Arg216X), as the most plausible candidate for causing the disease phenotype.  Sanger sequencing confirmed the homoallelic state of this mutation in the patient and the carrier state of the parents, and a screen of 192 Saudi controls was negative.  Immunoblot analysis of the patient’s cells consistently showed that he produced normal-sized ELOVL4, albeit at about a 45% reduced level.  This is surprising because his nonsense mutation predicted a 24 kDa protein compared to the normal 37 kDa ELOVL4.  The authors emphasized the importance of VLCFA synthesis in brain and cutaneous development and the critical role of ELOVL4 and VLCFAs in early brain development and in the integrity of the epidermal water barrier.  In addition, the findings demonstrated the power of combining homozygosity mapping with next-generation sequencing for identifying the cause of autosomal-recessive diseases even in simplex cases.

© CAGS 2024. All rights reserved.